16,580 Shares in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Acquired by Sigma Planning Corp

Sigma Planning Corp purchased a new stake in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 16,580 shares of the company’s stock, valued at approximately $51,000.

Aileron Therapeutics Stock Performance

Shares of ALRN opened at $4.92 on Tuesday. The company’s 50-day simple moving average is $5.42 and its 200-day simple moving average is $3.77. Aileron Therapeutics, Inc. has a 1 year low of $1.01 and a 1 year high of $7.42. The stock has a market capitalization of $83.49 million, a PE ratio of -1.46 and a beta of 2.22.

Aileron Therapeutics (NASDAQ:ALRN) last announced its earnings results on Monday, April 15th. The company reported ($1.54) earnings per share for the quarter. On average, sell-side analysts predict that Aileron Therapeutics, Inc. will post -0.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH increased their target price on Aileron Therapeutics from $9.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.